Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2003

01-06-2003

HER2 Codon 655 Polymorphism and Risk of Breast Cancer in African Americans and Whites

Authors: Robert Millikan, Allison Eaton, Kendra Worley, Lorna Biscocho, Elizabeth Hodgson, Wen-Yi Huang, Joseph Geradts, Mary Iacocca, David Cowan, Kathleen Conway, Lynn Dressler

Published in: Breast Cancer Research and Treatment | Issue 3/2003

Login to get access
Metadata
Title
HER2 Codon 655 Polymorphism and Risk of Breast Cancer in African Americans and Whites
Authors
Robert Millikan
Allison Eaton
Kendra Worley
Lorna Biscocho
Elizabeth Hodgson
Wen-Yi Huang
Joseph Geradts
Mary Iacocca
David Cowan
Kathleen Conway
Lynn Dressler
Publication date
01-06-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1024068525763

Other articles of this Issue 3/2003

Breast Cancer Research and Treatment 3/2003 Go to the issue

OriginalPaper

JNK/SAPK Mediates Doxorubicin-Induced Differentiation and Apoptosis in MCF-7 Breast Cancer Cells

OriginalPaper

Ornithine Decarboxylase (ODC) as a Prognostic Factor in Operable Breast Cancer

OriginalPaper

Progesterone Receptors A and B Differentially Affect the Growth of Estrogen-Dependent Human Breast Tumor Xenografts

OriginalPaper

Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

OriginalPaper

Inositol Hexaphosphate (IP6) Enhances the Anti-Proliferative Effects of Adriamycin and Tamoxifen in Breast Cancer

OriginalPaper

Progesterone Receptor Expression in Medroxyprogesterone Acetate-Induced Murine Mammary Carcinomas and Response to Endocrine Treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits